Turn Therapeutics says mouse study shows GX-03 cuts dermatitis severity 66%PUBT·Aug 20 at 07:03 AMTTRX-0.84%
Turn Therapeutics sells 135,000 shares in private placement for $1.35 millionPUBT·Aug 17 at 03:16 PMTTRX-0.84%
Ladenburg Thalmann & Co. Keeps Their Buy Rating on Turn Therapeutics Inc (TTRX)Tip Ranks·Aug 13 at 11:35 AMTTRX-0.84%
Turn Therapeutics releases corporate deck outlining GX-03 topical immunomodulator program for atopic dermatitisPUBT·Jul 28 at 07:09 AMTTRX-0.84%
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 ReadoutMarket Beat·Jul 11 at 12:02 PMTTRX-0.84%
Pre-market hot trades in US stocks: Turn Therapeutics pre-market down 7.18%; Microchip Tech pre-market up 3.86%Price Alert·Jul 9 at 06:57 AMTTRX-0.84%MCHP+0.36%
Popular pre-market trades in US stocks: Turn Therapeutics pre-market down 7.11%; Credo Tech pre-market down 4.01%Price Alert·Jul 8 at 06:02 AMTTRX-0.84%CRDO-0.34%
Turn Therapeutics expands GX-03 Phase 2 atopic dermatitis study after interim analysis shows broader efficacyPUBT·Jul 7 at 07:07 AMTTRX-0.84%
